In the clinics, the eligibility criteria for anti-EGFR therapy is based on RASwt status, whereas the CRC patients are not evaluated for EGFR expression levels; the fact that NK cells can effectively target EGFR- tumor cells could provide an ideal platform to treat metastatic CRC patients having variable levels of EGFR expression. This evidence concerns the gene EGFR and neoplasm.